To define the co-occurrence of IDH1/2 mutations and the presence of TERT promoter mutations, we determined the status of IDH1 and IDH2 mutations in the same cohort of 473 gliomas and identified mutations in 47.9% (227/473) of tumors (Fig. 1 and Table 1). The gene discussed is IDH2; the disease is glioma.